Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, PD, Italy.
Unit of Surgical Pathology & Cytopathology, Ospedale dell'Angelo, Mestre, VE, Italy.
Pathol Res Pract. 2022 Dec;240:154214. doi: 10.1016/j.prp.2022.154214. Epub 2022 Nov 9.
In sessile serrated lesions (SSLs) with adenomatous dysplasia, the dysplastic component and the serrated component without dysplasia should be considered as part of the same lesion, classified as SSL with dysplasia. However, some of these lesions may actually represent collisions between a serrated polyp and a conventional adenoma. Further supporting the "collision theory", conventional adenomatous dysplasia may be found in association with hyperplastic polyps (HPs). In order to determine the molecular and biological landscape of conventional type dysplasia in serrated lesions, we collected 17 cases of colorectal serrated lesions with adenomatous dysplasia, classifying them as SSL with dysplasia (n = 10) or as mixed lesions comprising a HP component and a conventional adenomatous component (n = 7). We characterized the dysplastic and the non-dysplastic component of each lesion, after microdissection, through the targeted mutational analysis of 11 commonly altered genes in colorectal cancer (AKT1, APC, BRAF, CTNNB1, KIT, KRAS, NRAS, PDGFRA, PIK3CA, PTEN and TP53). We also characterized MMR and p53 status by immunohistochemistry. Overall, 14/17 (82.4 %) cases harbored a mutation in at least one of the two components. The most altered genes were BRAF in 10/17 (58.8 %) cases, APC in 2/17 (11.8 %) and TP53 in 4/17 (23.5 %). Among the SSL with dysplasia, the mutational profile was concordant between the two components in 7/10 (70 %) cases, while among the mixed lesions, the mutational profile was concordant in 1/7 (14.3 %). In all but two cases of SSL with dysplasia, MMR status was concordant between the two components of the serrated lesions. Our findings suggest that adenomatous dysplasia may develop in SSL as part of the serrated lesion, even if some SSL with dysplasia may actually be collision lesions. On the other hand, the polyps that are morphologically classifiable as mixed lesions composed of a HP and a conventional adenomatous component are more likely to be collision lesions.
在无蒂锯齿状病变(SSL)伴腺瘤性异型增生中,异型增生成分和无异型增生的锯齿状成分应被视为同一病变的一部分,归类为伴异型增生的 SSL。然而,这些病变中的一些实际上可能代表锯齿状息肉和传统腺瘤之间的碰撞。进一步支持“碰撞理论”,在增生性息肉(HP)中可能发现传统腺瘤性异型增生。为了确定锯齿状病变中传统异型增生的分子和生物学特征,我们收集了 17 例结直肠锯齿状病变伴腺瘤性异型增生,将其分为伴异型增生的 SSL(n=10)或包含 HP 成分和传统腺瘤性成分的混合病变(n=7)。我们通过对 11 个常见的结直肠癌改变基因(AKT1、APC、BRAF、CTNNB1、KIT、KRAS、NRAS、PDGFRA、PIK3CA、PTEN 和 TP53)的靶向突变分析,对每个病变的异型增生和非异型增生成分进行了特征描述。我们还通过免疫组织化学方法对 MMR 和 p53 状态进行了特征描述。总体而言,17 例中有 14 例(82.4%)至少在两个成分中的一个中存在突变。最常改变的基因是 BRAF(10/17,58.8%)、APC(2/17,11.8%)和 TP53(4/17,23.5%)。在伴异型增生的 SSL 中,10/17(70%)病例的两个成分之间的突变谱一致,而在混合病变中,1/7(14.3%)病例的突变谱一致。除了 2 例伴异型增生的 SSL 外,锯齿状病变的两个成分之间的 MMR 状态一致。我们的研究结果表明,腺瘤性异型增生可能在 SSL 中作为锯齿状病变的一部分发展,即使一些伴异型增生的 SSL 实际上可能是碰撞病变。另一方面,形态学上可归类为由 HP 和传统腺瘤性成分组成的混合病变的息肉更有可能是碰撞病变。